GSTM4 is a microsatellite-containing EWS/FLI target involved in Ewing's sarcoma oncogenesis and therapeutic resistance - PubMed (original) (raw)
. 2009 Nov 19;28(46):4126-32.
doi: 10.1038/onc.2009.262. Epub 2009 Aug 31.
Affiliations
- PMID: 19718047
- DOI: 10.1038/onc.2009.262
GSTM4 is a microsatellite-containing EWS/FLI target involved in Ewing's sarcoma oncogenesis and therapeutic resistance
W Luo et al. Oncogene. 2009.
Abstract
Ewing's sarcoma is a malignant bone-associated tumor of children and young adults. Most cases of Ewing's sarcoma express the EWS/FLI fusion protein. EWS/FLI functions as an aberrant ETS-type transcription factor and serves as the master regulator of Ewing's sarcoma-transformed phenotype. We recently showed that EWS/FLI regulates one of its key targets, NR0B1, through a GGAA-microsatellite in its promoter. Whether other critical EWS/FLI targets are also regulated by GGAA-microsatellites was unknown. In this study, we combined transcriptional analysis, whole genome localization data, and RNA interference knockdown to identify glutathione S-transferase M4 (GSTM4) as a critical EWS/FLI target gene in Ewing's sarcoma. We found that EWS/FLI directly binds the GSTM4 promoter, and regulates GSTM4 expression through a GGAA-microsatellite in its promoter. Reduction of GSTM4 levels caused a loss of oncogenic transformation. Furthermore, reduction of GSTM4 resulted in an increased sensitivity of Ewing's sarcoma cells to chemotherapeutic agents, suggesting a role for this protein in drug resistance. Consistent with this hypothesis, patients with Ewing's sarcoma whose tumors had higher levels of GSTM4 expression had worse outcomes than those with lower expression levels. These data show that GSTM4 contributes to the cancerous behavior of Ewing's sarcoma and define a wider role for GGAA-microsatellites in EWS/FLI function than previously appreciated. These data also suggest a novel therapeutic resistance mechanism, in which the central oncogenic abnormality directly regulates a resistance gene.
Similar articles
- DAX1, a direct target of EWS/FLI1 oncoprotein, is a principal regulator of cell-cycle progression in Ewing's tumor cells.
García-Aragoncillo E, Carrillo J, Lalli E, Agra N, Gómez-López G, Pestaña A, Alonso J. García-Aragoncillo E, et al. Oncogene. 2008 Oct 9;27(46):6034-43. doi: 10.1038/onc.2008.203. Epub 2008 Jun 30. Oncogene. 2008. PMID: 18591936 - Targeting of EWS/FLI-1 by RNA interference attenuates the tumor phenotype of Ewing's sarcoma cells in vitro.
Chansky HA, Barahmand-Pour F, Mei Q, Kahn-Farooqi W, Zielinska-Kwiatkowska A, Blackburn M, Chansky K, Conrad EU 3rd, Bruckner JD, Greenlee TK, Yang L. Chansky HA, et al. J Orthop Res. 2004 Jul;22(4):910-7. doi: 10.1016/j.orthres.2003.12.008. J Orthop Res. 2004. PMID: 15183454 - A link between basic fibroblast growth factor (bFGF) and EWS/FLI-1 in Ewing's sarcoma cells.
Girnita L, Girnita A, Wang M, Meis-Kindblom JM, Kindblom LG, Larsson O. Girnita L, et al. Oncogene. 2000 Aug 31;19(37):4298-301. doi: 10.1038/sj.onc.1203755. Oncogene. 2000. PMID: 10980604 - The role of Fli-1 in normal cell function and malignant transformation.
Truong AH, Ben-David Y. Truong AH, et al. Oncogene. 2000 Dec 18;19(55):6482-9. doi: 10.1038/sj.onc.1204042. Oncogene. 2000. PMID: 11175364 Review. - The Biology of Ewing sarcoma.
Riggi N, Stamenkovic I. Riggi N, et al. Cancer Lett. 2007 Aug 28;254(1):1-10. doi: 10.1016/j.canlet.2006.12.009. Epub 2007 Jan 23. Cancer Lett. 2007. PMID: 17250957 Review.
Cited by
- Multi-omics Mendelian randomization integrating GWAS, eQTL and pQTL data revealed GSTM4 as a potential drug target for migraine.
Sun X, Chen B, Qi Y, Wei M, Chen W, Wu X, Wang Q, Li J, Lei X, Luo G. Sun X, et al. J Headache Pain. 2024 Jul 22;25(1):117. doi: 10.1186/s10194-024-01828-w. J Headache Pain. 2024. PMID: 39039470 Free PMC article. - Construction of novel 7 integrin-related gene signatures in thyroid cancer construction of model based on integrin genes.
Zhang D, Xiang KF, Xiang C, Wu Y, Wang L. Zhang D, et al. Medicine (Baltimore). 2023 Dec 15;102(50):e36412. doi: 10.1097/MD.0000000000036412. Medicine (Baltimore). 2023. PMID: 38115319 Free PMC article. - EWS/FLI1 Characterization, Activation, Repression, Target Genes and Therapeutic Opportunities in Ewing Sarcoma.
Yasir M, Park J, Chun W. Yasir M, et al. Int J Mol Sci. 2023 Oct 14;24(20):15173. doi: 10.3390/ijms242015173. Int J Mol Sci. 2023. PMID: 37894854 Free PMC article. Review. - Targeted Therapy for EWS-FLI1 in Ewing Sarcoma.
Gong H, Xue B, Ru J, Pei G, Li Y. Gong H, et al. Cancers (Basel). 2023 Aug 9;15(16):4035. doi: 10.3390/cancers15164035. Cancers (Basel). 2023. PMID: 37627063 Free PMC article. Review. - Interlaboratory Variability in the Madin-Darby Canine Kidney Cell Proteome.
Harwood MD, Zettl K, Weinheimer M, Pilla-Reddy V, Shen H, Jacobs F, Chu X, Huth F, Nakakariya M, Chothe PP, Neuhoff S, Wiśniewski JR. Harwood MD, et al. Mol Pharm. 2023 Jul 3;20(7):3505-3518. doi: 10.1021/acs.molpharmaceut.3c00108. Epub 2023 Jun 7. Mol Pharm. 2023. PMID: 37283406 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical